[Global Times] According to a report from Japan's Kyodo News Agency on May 18th, a research team from the University of Kyoto's chemical biology professor Shinohara Masaru and others announced on the 18th that it has developed an anti-viral compound that can inhibit cervical cancer. At present, cervical cancer is prevented by vaccination against a virus-infected vaccine, but reports have also been shown to lead to impaired health. Ebara said the compound "may become a new drug candidate for the prevention of cervical cancer." This achievement was published in the online edition of the American Medical Journal. It is reported that the team will conduct clinical trials for patients with early cervical cancer at Kyoto University Affiliated Hospital in 2018 to verify its safety and effectiveness. In vitro, the researchers used this compound in epithelial cells of patients infected with human papillomavirus (HPV). As a result, the proliferation of HPV was inhibited. Human cervical cancer is transplanted to mice, and the use of this compound can also inhibit its proliferation. No side effects were reported. HPV is the main cause of cervical cancer due to sexual behavior infection. Young patients with cervical cancer are rapidly increasing. In April 2013, Japan targeted female students in sixth grade primary school to first grade high school. In principle, it is free and regularly vaccinated. However, the Ministry of Health, Labour and Welfare stopped the encouragement of vaccination in June 2013 due to the presence of side effects such as delirium. (Reporter Wang Huan) Posture Corrector,Posture Support,Posture Corrector Device,Back Brace Posture Corrector XIAMEN DORRELLA HEALTH TECHNOLOGY CO.,LTD , https://www.dinglimed.com